Letter to the editor from Pant .
作者信息
Pant Shubham, Moyers Justin T, Naing Aung
机构信息
Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA.
Division of Hematology & Oncology, Department of Medicine, University of California Irvine, Orange, California, USA.
出版信息
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003991.
Abstract
摘要
相似文献
1
Letter to the editor from Pant .潘特致编辑的信。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003991.
2
Comments to the Letter to the Editor of S. Shahsavari et al. concerning "Predicting medical complications in spine surgery: evaluation of a novel online risk calculator" by M. F. Kasparek et al. (Eur Spine J: doi:10.1007/s00586-018-5707-9) and the reply to the Letter to the Editor of S. Shahsavari et al. concerning "Predicting medical complications in spine surgery: evaluation of a novel online risk calculator" by M. F. Kasparek et al. (Eur Spine J: doi:10.1007/s00586-018-5707-9).致《欧洲脊柱杂志》编辑的信的评论，内容涉及S. Shahsavari等人对M. F. Kasparek等人所著的“脊柱手术中医疗并发症的预测：一种新型在线风险计算器的评估”（《欧洲脊柱杂志》：doi:10.1007/s00586-018-5707-9）的评论，以及对S. Shahsavari等人致编辑信的回复，该信同样涉及M. F. Kasparek等人所著的“脊柱手术中医疗并发症的预测：一种新型在线风险计算器的评估”（《欧洲脊柱杂志》：doi:10.1007/s00586-018-5707-9） 。
Eur Spine J. 2018 Nov;27(11):2889-2890. doi: 10.1007/s00586-018-5783-x. Epub 2018 Oct 16.
3
Response to letter to the editor by Dr Wages et al.对韦奇斯博士等人致编辑信件的回复
Stat Med. 2014 May 30;33(12):2159-60. doi: 10.1002/sim.5972.
4
Letter to the editor: a comment on Lynch et al. (2009).
Psychol Med. 2010 May;40(5):877-80. doi: 10.1017/S0033291709991838. Epub 2009 Nov 17.
5
Answer to the Letter to the Editor of Qi Sun et al. concerning "Robot-assisted and conventional freehand pedicle screw placement: a systematic review and meta-analysis of randomized controlled trials" by Gao ST, et al. (Eur Spine J; 2017: DOI 10.1007/s00586-017-5333-y).对孙启等人致编辑信的回复，该信涉及高思婷等人发表的《机器人辅助与传统徒手椎弓根螺钉置入：随机对照试验的系统评价和荟萃分析》（《欧洲脊柱杂志》；2017年：DOI 10.1007/s00586-017-5333-y）
Eur Spine J. 2018 Apr;27(4):933-934. doi: 10.1007/s00586-018-5493-4. Epub 2018 Jan 30.
6
Letter to the editor regarding Davidson et al.致编辑的关于戴维森等人的信
Am J Med. 2006 Feb;119(2):186; author reply 186. doi: 10.1016/j.amjmed.2005.07.048.
7
Answer to the letter to the editor of Christensen S et al. concerning "The role of non-rigid cervical collar in pain relief and functional restoration after whiplash injury-a systematic review and a pooled analysis of randomized controlled trials" by Ricciardi L et al. (Eur Spine J; [2019] 28:1821-1828).对克里斯滕森等人致编辑信的回复，该信涉及里恰尔迪等人的“非刚性颈托在挥鞭伤后疼痛缓解和功能恢复中的作用——系统评价与随机对照试验的汇总分析”（《欧洲脊柱杂志》；[2019]28:1821 - 1828）。
Eur Spine J. 2020 May;29(5):1193-1195. doi: 10.1007/s00586-020-06375-x. Epub 2020 Mar 19.
8
Letter to the editor in response to "The evidence for pharmacological treatment of neuropathic pain," by Finnerup et al.致编辑的信：回应芬内鲁普等人的《神经性疼痛药物治疗的证据》
Pain. 2011 Jun;152(6):1440. doi: 10.1016/j.pain.2011.03.031. Epub 2011 Apr 21.
9
Letter to the editor responding to Anderson et al.'s 2020 letter regarding Rice et al. (2020).致编辑的信，回应安德森等人于2020年就赖斯等人（2020年）的信件所写的内容。
Food Chem Toxicol. 2020 Nov;145:111755. doi: 10.1016/j.fct.2020.111755. Epub 2020 Sep 18.
10
Response to Kujawa et al. letter-to-the-editor.
Schizophr Res. 2006 May;84(1):172-3. doi: 10.1016/j.schres.2005.11.010. Epub 2006 Mar 24.
引用本文的文献
1
Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial.帕博利珠单抗治疗晚期多种罕见癌症患者：一项2期篮子试验的结果
J Immunother Precis Oncol. 2025 Apr 10;8(2):143-151. doi: 10.36401/JIPO-24-27. eCollection 2025 May.
本文引用的文献
1
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).帕博利珠单抗单药治疗复发性或转移性皮肤鳞状细胞癌：一项单臂 II 期试验（KEYNOTE-629）。
J Clin Oncol. 2020 Sep 1;38(25):2916-2925. doi: 10.1200/JCO.19.03054. Epub 2020 Jul 16.
2
Phase 2 study of pembrolizumab in patients with advanced rare cancers.派姆单抗治疗晚期罕见癌症患者的 II 期研究。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000347.
3
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
4
Case Report: Primary Orbital Squamous Cell Carcinoma.病例报告：原发性眼眶鳞状细胞癌。
Ocul Oncol Pathol. 2019 Jan;5(1):60-65. doi: 10.1159/000490060. Epub 2018 Jun 29.
5
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.用于治疗眼眶鳞状细胞癌的表皮生长因子受体抑制剂
Arch Ophthalmol. 2012 Dec;130(12):1608-11. doi: 10.1001/archophthalmol.2012.2515.
Zotero 插件